(InDi@), an emerging leader in molecular diagnostics, today announced

that the company has launched a new operating division, InDi


that is creating a new generation of PET imaging probes using the

company's innovative protein catalyzed capture (PCC) agent


PCCs, initially developed for in vitro molecular diagnostics, will be

employed as rationally designed, in vivo diagnostic imaging probes

that mimic the properties of antibodies and biologics in PET molecular

imaging, with the benefit of being chemically stable, synthetic


Concurrently, the company announced that it has appointed Norman



as the president of InDi Imaging. Dr. Hardman, a well-respected

biotechnology executive, has a long track record of successfully

commercializing new molecular technologies. The company also announced

that Michael Phelps,


Norton Simon Professor, chairman of the UCLA Department of Molecular

and Medical Pharmacology and the inventor of PET, has been appointed

to InDi Imaging as an advisor. Integrated Diagnostics' other division,

InDi Dx?, will continue to focus on in vitro diagnostic medicine. Its

first diagnostic test, a blood based protein test for the detection of

lung cancer in patients with intermediate size pulmonary


is scheduled for commercial launch in the first half of 2013.

"InDi Imaging is seeking to provide whole body imaging assays with PET

of all tissues of the body to examine the primary tumor in cancers and

metastases in different organs that are known to have different

biological characteristics to supplant more conventional diagnostic

modalities through real time imaging with PET using PCC technology,"

said Albert "Al" A. Luderer,


CEO of Integrated Diagnostics. "Norm Hardman brings a wealth of

experience and success in R&D, pharmaceuticals and biotech. I believe

Norm is uniquely positioned to lead InDi Imaging as we create a new

world of imaging products with PCC technology that are coupled to our

in vitro blood based molecular diagnostics."

PCCs are stable, synthetic, rationally designed chemical compositions

with small-molecule like properties designed to detect designated

motifs on any target protein through chemical diversity in the PCCs

for arrays of protein targets. InDi licensed PCCs from the California

Institute of Technology (Caltech). The technology is based on

inventions pioneered by Jim Heath,


a Caltech and UCLA professor, InDi co-founder and board member. The

team at InDi, under the direction of Paul Kearney,


the company's president, CSO, and co-founder, is adapting PCCs for in

vivo diagnostic imaging applications. PCCs are manufactured using



a process that allows scientists to join ("click") together molecular

components with unusual precision and stability with high selectivity

to the target protein. InDi has obtained a license to use click

chemistry from the Scripps Research Institute. The company plans to

pursue the first human studies of its PCC-based imaging products over

the next 12-18 months.

"PCCs are incredibly versatile because they are built using the

principles of modular chemistry. That means they can be optimized for

use as in vivo imaging PET probes, enabling us to simultaneously

pursue multiple disease targets in a way that is difficult or

impossible using more traditional antibody- or phage-display

approaches," said Dr. Hardman. "I am very excited to join Al, Jim,

Paul and the rest of the InDi team in developing new imaging products

that will be clinically significant and commercially successful. I'm

also looking forward to working closely with Dr. Phelps in the

application of PCC technology to develop the next-generation of

imaging probes with superior performance in PET imaging and

informative diagnosis of the biology of disease in patients."

Dr. Phelps is the inventor of PET, a molecular imaging technique that

provides in vivo images of biological processes, blood flow,

metabolism, cell communication systems, drug interactions and gene

expression. The technology has many important clinical applications in

the diagnosis of human disease, and monitoring of therapeutic

modalities. There are 2,400 clinical PET imaging centers in America,

as well as PET clinical services throughout the rest of the world.

While uniquely providing molecular imaging diagnostics of disease, the

unique principles of PET have provided its molecular imaging

diagnostics in approximately 37 million clinical studies without a

single reported complication.

"We are very pleased to welcome Dr. Michael Phelps as an advisor to

InDi Imaging," said Dr. Luderer. "He is an unparalleled scholar and

entrepreneur in molecular imaging whose counsel will be essential to

the technical and clinical success of PCC technology as an innovative

new approach to molecular diagnostic imaging of disease."

About Dr. Hardman

Prior to joining Integrated Diagnostics, Dr. Hardman was the president

and CEO of Oxalis Partners, a strategic consultancy to US and EU

biotechnology companies and venture capital firms. He is currently

non-executive director of Chelsea Therapeutics, Inc. and has

previously held senior management roles in several US-based

biotechnology companies, including: president and CEO of Amicus

Therapeutics; CEO of the UK Medical Research Council (MRC) Technology

Transfer organization; senior VP of technology for Enzon

Pharmaceuticals; COO of Onyx Pharmaceuticals; and president and COO of


Earlier in his career, Dr. Hardman served as head of R&D at Ciba-Geigy

UK and played a central role in the integration of the global R&D

organization during the merger of Ciba-Geigy and Sandoz to form

Novartis AG, becoming head of UK R&D Operations in the merged entity.

He has been involved at various stages in the R&D of several important

pharmaceutical products, including: Gleevec, Xolair, Nexavar, Amigal

and Plicera.

Dr. Hardman graduated in chemistry from the University of London,

U.K., and obtained his Ph.D. in biochemistry, from the University of

Manchester. His postdoctoral training included a two-year period as a

Medical Research Council fellow, and as a postdoctoral fellow at

Harvard Medical School. Dr. Hardman is an honorary professor of

medical sciences at the University of Aberdeen, and currently serves

as VP of the Aberdeen University Development Trust. He is a fellow of

the Royal Society of Chemistry and a fellow of the Institute of


About Dr. Phelps

Michael Phelps is the Norton Simon Professor and chair of the UCLA

Department of Molecular and Medical Pharmacology and director of the

Crump Institute for Molecular Imaging.

Dr. Phelps is the inventor of PET imaging technology, which is used in

research to study the biological basis of normal organ function in

health and the biological transitions to disease and to guide new

therapies in academia research and pharmaceutical companies. PET is

used in clinical practice in the early detection, characterization and

evaluation of the therapeutic responses in cancer, neurological

disorders and cardiovascular disease.

Dr. Phelps has received numerous awards and honors, including: the

Pasarow Foundation Award, the Rosenthal Foundation Award, the George

Von Hevesy Prize (won twice; Von Hevesy won the Nobel Prize for the

principles of tracer method), the Sarah L. Poiley Memorial Award,

Kettering Prize, General Motors Cancer Research Foundation; the Ernest

O. Lawrence Presidential Award, the Paul Aebersold Award, appointment

as chair of the Nobel Symposium, election to the Institute of Medicine

of the National Academy of Sciences, Enrico Fermi Presidential Award

from President Clinton and election to the National Academy of

Sciences. He has published 720 peer-reviewed scientific articles and

four textbooks.

About Integrated Diagnostics



mission is to build new generations of cost-effective, large-scale

molecular diagnostic products for improved diagnosis of complex

diseases with high unmet needs. InDi Dx?, the company's in vitro

diagnostic medicine division, is developing complex

laboratory-developed molecular diagnostic tests that assist physicians

with the early diagnosis of diseases like lung




by simultaneously monitoring tens to hundreds of disease molecular

markers. Integrated Diagnostics' other division, InDi Imaging, is

creating new generations of in vivo molecular imaging diagnostic

products based on a novel class of small-molecule diagnostic imaging

probes that mimic the properties of biologics and antibodies using

InDi's protein-catalyzed capture (PCCs) agent technology.

The company, co-founded in October 2009 by systems biology pioneer Dr.



is conceptually based on a systems view of disease where

pathophysiology arises from disease-perturbed networks of proteins,

genes, and other molecules. Investors include InterWest Partners, The

Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual

property is exclusively licensed from the Institute for Systems

Biology and Caltech. Learn more at